Can brigatinib/brigatinib be used in combination with cetuximab?

Brigatinib/Brigatinib is mainly used to treat specific types of non-small cell lung cancer (NSCLC), while cetuximab (Cetuximab) is commonly used to treat colorectal cancer and head and neck cancer. There are currently few clinical data and research results on the combined use of Brigatinib and Cetuximab. The combined use of drugs requires consideration of their interactions, safety and efficacy, and must be done under close monitoring.

For severely ill patients with non-small cell lung cancer (NSCLC) who require life-saving treatment, there is currently no reported evidence for the use of drugs that specifically target the epidermal growth factor receptor (EGFR) p.C797S mutation, which is known to cause Resistance to third-generation tyrosine kinase inhibitors (TKIs) was clinically reported on two patients with non-small cell lung cancer who initially carried an EGFR-sensitizing mutation and both received treatment with the third-generation TKI drug osimertinib.

Next-generation sequencing testing performed before starting fifth-line treatment in severely ill patients revealed the presence of the EGFR p.C797S mutation in both patients, indicating acquired resistance. During the fifth line of treatment, the combination of brigatinib and cetuximab proved crucial in saving critically ill patients, modestly extending their overall survival. Our results suggest that the combination of brigatinib and cetuximab can serve as a potentially life-saving treatment strategy for severely ill patients with non-small cell lung cancer, especially those who exhibit EGFR p.C797S-mediated resistance. However, further research is needed to validate and extend these promising findings.